How an mRNA-encoded antibody platform could accelerate therapies to clinic Therapeutic antibody production is traditionally complex and costly, which drives up treatment prices. However, encoding antibodies with mRNA offers a potential solution to many of these challenges, making the process…
mRNA for Antibody Manufacturing In collaboration, Charles River Lab and Vernal Biosciences released this scientific poster. Since its release, new advancements have been made and new data is available to share. Join the webinar on December 12 to dive into…
In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced…
Nature Nanotechnology: Tissue-Specific mRNA Therapeutic Delivery Researchers have developed a combinatorial design of siloxane-incorporated LNPs to enhance tissue-specific mRNA therapeutic delivery. This article explains how this approach improves intracellular processing and stability of mRNA, showing promise for targeted treatments and…
In this video series exploring biotech innovation, Christian Cobaugh, founder and CEO of Vernal, discusses the critical role of analytical services in the success of mRNA and lipid nanoparticles (LNPs) therapeutics. Interviewed by Kristyn Cook, Executive Director of Marketing, he…
Speaking of Mol Bio Podcast In the latest episode (Season 2, Episode 8) of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The…
Rapid Single Epitope mRNA Production This article presents a synthetic DNA template (SDT) process for manufacturing single epitope mRNA, offering a flexible, cost-efficient, and rapid alternative to traditional plasmid DNA templates (PDT). Read the article to explore what can be…
Authored by: Christian Cobaugh, Grant Henderson and Khaled Yamout The FDA’s new guidance clarifies eligible Platform Technologies must adhere to the statutory definition and require consistent CMC processes. Applicants can recycle features across products, while those lacking assets can leverage CDMOs like…
Phase 2b Autoimmune CAR-T Win Congratulations to Cartesian Therapeutics on their Phase 2b autoimmune CAR-T trial success—shifting the intensity of the cell therapy paradigm! This milestone is a testament to their innovation. It’s exciting to see mRNA as part of…
mRNA Capping TechnologiesExplore this study, which compares two important mRNA capping technologies by evaluating the mRNA integrity, percent Cap1 content, dsRNA content, in vivo expression and innate immune activation in mice. Download the Poster 7 Key Benefits of a US-Based…
From the FounderWelcome to the NEW monthly mRNA newsletter! In this monthly update, we will share the latest breakthroughs, insights, and innovations in mRNA and mRNA-LNP technology. By reading these updates, you will gain a competitive edge, stay ahead of…
Poster Abstract: The mRNA Poly(A) Sizing Methods poster shows the poly (A) tail region of an mRNA functions to stabilize the mRNA and enable translation of the protein. Due to its biological importance of an mRNA’s poly(A) tail, the length…